Citadel Advisors - NEOLEUKIN THERAPEUTICS INC ownership

Quarter-by-quarter ownership
Citadel Advisors ownership history of NEOLEUKIN THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$43,651
+351.9%
52,591
+281.1%
0.00%
Q1 2023$9,660
-93.7%
13,800
-90.7%
0.00%
Q2 2022$153,000
-13.6%
148,402
+58.5%
0.00%
Q1 2022$177,000
-67.0%
93,640
-15.8%
0.00%
Q4 2021$536,000
+232.9%
111,174
+397.1%
0.00%
Q3 2021$161,000
-91.1%
22,366
-88.5%
0.00%
Q2 2021$1,802,000
-26.7%
195,262
-2.2%
0.00%
Q1 2021$2,458,000
-10.6%
199,631
+2.5%
0.00%
Q4 2020$2,748,000
-37.2%
194,856
-46.6%
0.00%
-100.0%
Q3 2020$4,377,000
+280.3%
364,759
+426.1%
0.00%
Q2 2020$1,151,000
-7.5%
69,333
-36.6%
0.00%
Q1 2020$1,244,000109,3170.00%
Other shareholders
NEOLEUKIN THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Opaleye Management Inc. 1,386,300$19,547,0002.55%
EcoR1 Capital, LLC 3,122,704$44,030,0002.37%
Redmile Group, LLC 4,131,869$58,259,0000.70%
Boxer Capital, LLC 1,501,058$21,165,0000.68%
HighVista Strategies LLC 69,727$983,0000.63%
Baker Brothers Advisors 3,821,740$53,887,0000.20%
Highland Private Wealth Management 93,998$1,326,0000.12%
Sio Capital Management, LLC 38,312$540,0000.11%
Point72 Asset Management, L.P. 1,195,725$16,860,0000.08%
Granahan Investment Management 246,299$3,473,0000.08%
View complete list of NEOLEUKIN THERAPEUTICS INC shareholders